Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Neuer Top-Geologe an Bord - zündet jetzt die nächste Kursrakete?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AA7B | ISIN: US05464T1043 | Ticker-Symbol: 19X
Tradegate
04.06.25 | 19:56
95,10 Euro
+0,34 % +0,32
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
AXSOME THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
AXSOME THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
94,0695,4004.06.
94,3295,2604.06.

Aktuelle News zur AXSOME THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiAxsome Therapeutics auf der 45. jährlichen William Blair Growth Stock Konferenz: Strategische Einblicke6
DiAxsome initiated with an Outperform at Oppenheimer on revenue boost4
DiOppenheimer initiates Axsome Therapeutics stock with outperform rating12
MoH.C. Wainwright maintains buy rating on Axsome stock after settlement7
28.05.Axsome Therapeutics, Inc.: Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting19
27.05.Axsome Agrees With Hetero Labs To Settle Patent Litigation Related To SUNOSI1
27.05.Axsome settles patent dispute with Hetero Labs over Sunosi generic2
AXSOME THERAPEUTICS Aktie jetzt für 0€ handeln
27.05.Axsome Therapeutics, Inc.: Axsome Therapeutics Settles SUNOSI (solriamfetol) Patent Litigation with Hetero Labs Ltd.272NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders...
► Artikel lesen
27.05.Axsome Therapeutics, Inc. - 8-K, Current Report2
22.05.Expert Outlook: Axsome Therapeutics Through The Eyes Of 16 Analysts21
15.05.Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis19
13.05.Axsome Enters $570 Mln Term Loan And Revolving Credit Facility With Blackstone341WASHINGTON (dpa-AFX) - Biopharmaceutical company Axsome Therapeutics, Inc. (AXSM) announced that it has entered into a $570 million term loan and revolving credit facility with funds managed...
► Artikel lesen
13.05.Axsome Therapeutics enters $570M term loan, credit facility with Blackstone4
13.05.Axsome sichert sich Kreditfazilität von 570 Millionen US-Dollar von Blackstone8
13.05.Axsome Therapeutics, Inc.: Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone173Previous term loan facility retired NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous...
► Artikel lesen
13.05.Axsome Therapeutics, Inc. - 8-K, Current Report3
06.05.AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y4
06.05.BofA raises Axsome stock target to $176, maintains buy rating7
05.05.Axsome Therapeutics, Inc. - 10-Q, Quarterly Report3
05.05.Axsome targets FDA decision on AXS-14 for fibromyalgia in Q2 20254
Seite:  Weiter >>
137 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3